In this "Things You Need to Know" series on emerging technologies, we will learn from prominent scientists, entrepreneurs, and investors about their successes, struggles, and the things they wished they knew before starting their journey.
Sponsored by MedChemExpress
Are you an academic drug discovery scientist with a project idea you’d like to partner with industry or other funding agencies? Then help us build the Idea-Matched Proposals for Academic Translation (IMPACT) Database, the latest initiative of the Professional Advancement and Educational Resources (PAVER) committee of the ADDC! Both IMPACT and PAVER are designed to capitalize on the strength of our membership by integrating aspects of the three pillars of the ADDC: Education, Community, and Partnership. This month we are sponsoring a webinar to highlight end-users of the IMPACT database who serve as representatives of partnership strategies. Additionally, by participating in this webinar, we hope you will gain insight into how to craft your science to entice partnerships to help you move from bench to bedside.
This webinar will feature Maaike Everts, Ph.D., Executive Director, Translational Therapeutics Accelerator, who is looking for academic projects that would benefit from nonprofit funding, Florian Montel, Ph.D., the head of Open Innovation at Boehringer-Ingelheim, who will speak about BI’s OpenM Initiative to provide access to highly characterized molecules from BI’s collection to push the boundaries of clinical applications, and Saghar Nourian, Ph.D. from AstraZeneca, a Senior Scientist interested in promoting external collaborations with universities and start-up companies.
This Seminar series is hosted by the Academic Drug Discovery Consortium (ADDC). The ADDC is a professional society dedicated to building the community of academic drug discovery labs and the companies, universities, and government agencies that support and partner with these centers.